260 related articles for article (PubMed ID: 27203405)
1. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Nieto Y; Valdez BC; Thall PF; Ahmed S; Jones RB; Hosing C; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Alousi A; Shah N; Bashir Q; Liu Y; Oki Y; Hagemeister F; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1914-20. PubMed ID: 26071868
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
Nieto Y; Popat U; Anderlini P; Valdez B; Andersson B; Liu P; Hosing C; Shpall EJ; Alousi A; Kebriaei P; Qazilbash M; Parmar S; Bashir Q; Shah N; Khouri I; Rondon G; Champlin R; Jones RB
Biol Blood Marrow Transplant; 2013 Mar; 19(3):410-7. PubMed ID: 23128322
[TBL] [Abstract][Full Text] [Related]
4. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Nieto Y; Thall P; Valdez B; Andersson B; Popat U; Anderlini P; Shpall EJ; Bassett R; Alousi A; Hosing C; Kebriaei P; Qazilbash M; Frazier E; Gulbis A; Chancoco C; Bashir Q; Ciurea S; Khouri I; Parmar S; Shah N; Worth L; Rondon G; Champlin R; Jones RB
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1677-86. PubMed ID: 22643322
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779
[TBL] [Abstract][Full Text] [Related]
6. A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Ji J; Liu Z; Kuang P; Dong T; Chen X; Li J; Zhang C; Liu J; Zhang L; Shen K; Liu T
Int J Cancer; 2021 Dec; 149(12):2075-2082. PubMed ID: 34398971
[TBL] [Abstract][Full Text] [Related]
7. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Champlin RE; Andersson BS
Leuk Lymphoma; 2017 Nov; 58(11):2705-2716. PubMed ID: 28394191
[TBL] [Abstract][Full Text] [Related]
8. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
10. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Alkhaldi H; Reinhardt A; Barnett M; Kundu S; Hosing C; Ramdial J; Saini N; Srour S; Alousi A; Kebriaei P; Popat U; Qazilbash M; Champlin R; Shpall EJ; Gulbis A; Shigle TL; Dabaja B; Pinnix C; Ahmed S; Steiner R; Andersson BS; Nieto Y
Transplant Cell Ther; 2023 Nov; 29(11):690-694. PubMed ID: 37607645
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
12. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
13. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
Kebriaei P; Madden T; Kazerooni R; Wang X; Thall PF; Ledesma C; Nieto Y; Shpall EJ; Hosing C; Qazilbash M; Popat U; Khouri I; Champlin RE; Jones RB; Andersson BS
Biol Blood Marrow Transplant; 2011 Mar; 17(3):412-20. PubMed ID: 20674757
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
[TBL] [Abstract][Full Text] [Related]
16. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
[TBL] [Abstract][Full Text] [Related]
17. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
Nieto Y; Gruschkus S; Valdez BC; Jones RB; Anderlini P; Hosing C; Popat U; Qazilbash M; Kebriaei P; Alousi A; Saini N; Srour S; Rezvani K; Ramdial J; Barnett M; Gulbis A; Shigle TL; Ahmed S; Iyer S; Lee H; Nair R; Parmar S; Steiner R; Dabaja B; Pinnix C; Gunther J; Cuglievan B; Mahadeo K; Khazal S; Chuang H; Champlin R; Shpall EJ; Andersson BS
Haematologica; 2022 Apr; 107(4):899-908. PubMed ID: 33951890
[TBL] [Abstract][Full Text] [Related]
18. Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
Shinozuka K; Tang H; Jones RB; Li D; Nieto Y
Biol Blood Marrow Transplant; 2016 May; 22(5):843-9. PubMed ID: 26743341
[TBL] [Abstract][Full Text] [Related]
19. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Yazbeck V; Shafer D; Perkins EB; Coppola D; Sokol L; Richards KL; Shea T; Ruan J; Parekh S; Strair R; Flowers C; Morgan D; Kmieciak M; Bose P; Kimball A; Badros AZ; Baz R; Lin HY; Zhao X; Reich RR; Tombes MB; Shrader E; Sankala H; Roberts JD; Sullivan D; Grant S; Holkova B
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):569-575.e1. PubMed ID: 30122201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
